Brandon Huffman, MD

Results of randomized phase II #PDAC trial that will be a benchmark for future trials. Patients receiving 2nd-line gemcitabine/nab-paclitaxel alone after FOLFIRINOX had median OS of 6.6 months, the median PFS was 2.7 months, and the ORR was 2.9%. ⬇️⬇️⬇️ jamanetwork.com/journals/jaman…

#KRASatAACR26 LB407 / 7 - Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC) April 21 MiniSymposium: Late-Breaking Research abstractsonline.com/pp8/?fbclid=Iw… @AACR @CentralParkWMD @aparna1024 #KRAS #AACR26

🆕 @ScienceMagazine An exciting new approach vs pancreatic cancer: "cancer interception" Considered ubiquitous, the pancreas in healthy adults has hundreds of PanINs of microscopic premalignant cancer that can be regressed in the experimental model science.org/doi/10.1126/sc… science.org/doi/10.1126/sc…

🧬 Novel KRAS G12D inhibitor INCB161734 showed promising activity in patients with heavily pretreated #pancreaticcancer: • ORR: 37% • DCR: 78% • Early molecular response: 66% 👨‍⚕️ Presented by Zev Wainberg, MD, MSc at #GI26; discussant Andrew H. Ko, MD 🔗 ascopost.com/news/march-202…

Continuing with our #GI26 updates- we briefly review promising early phase data for INCB161734 in advanced KRAS G12D mt pancreatic adenocarcinoma. KRAS is no longer “undruggable”. @GIMedOnc @TimothyJBrownMD @UGrewalMD Link to podcast- oncologynexus.com/podcast/gut-on…

While bi-allelic loss of function of homologous recombination repair genes is not sufficient for sustained response to PARP inhibitors in #PancreaticCancer, it is at least necessary. Differentiation of mono v bi allelic LOF on molecular assays is a must. aacrjournals.org/clincancerres/…

@CentralParkWMD @DanaFarber_Hale @KReissMD @PennCancer @CentralParkWMD - Excluding HRD and MSI- high. In @KReissMD initial study, there was a median PFS of 7.6 months with niraparib/ipi in patients without known DNA damage repair alterations. thelancet.com/journals/lanon…

@BHuffmanMD @DanaFarber_Hale @KReissMD @PennCancer Congratulations! Looking forward to this! All-comers? Or HRD enrichment?

Now Open @DanaFarber_Hale: Phase 2 study of niraparib + ipilimumab vs chemo as maintenance therapy for metastatic pancreatic cancer after 4-6 months FOLFIRINOX. Excited to collaborate with @KReissMD @PennCancer on this important work! Learn more: clinicaltrials.gov/study/NCT06747…

Updates ph1 INCB161734 KRAS G12Di #PDAC #GI26 ➡️ sel On/Off, n=61 mono (1200mg) n=44 combo ➡️ORR mono 37% (n=41) ➡️ ctDNA 66% on 1200mg molecular response (≥90% reduction) ➡️ tolerated with GnP and mFFX (data on n=23) ➡️ KRAS CN - ‼️resistance @ASCO @myESMO @OncoAlert

Congratulations to @DanaFarber's Drs. Brian Wolpin and Andrew Aguirre - recipients of a 2026 Mark Foundation-AACR-Lustgarten Foundation Early Detection Award for their research in KRAS-mutant pancreatic cancer. @TheMarkFdn @AACR @lustgartenfdn @break_cancer @TinasWish @DanaFarber_Hale ➡️ bit.ly/4acXj7w

Are liquid biopsy tools that capture gene expression the future of precision oncology? We tackle this question and share our vision for Precision Oncology 2.0 in @JCO_ASCO: ascopubs.org/doi/10.1200/JC… with @DrChoueiri , #MattFreedman, @SylvanBacaLab at @DanaFarber .

Excited, happy and proud to share our @Nature publication on neoadjuvant ICB in pMMR colon cancer; #NICHE! We provide validation of previous clinical results, plus extensive and comprehensive analyses of Overdue tweetorial below❗️ nature.com/articles/s4158…

NCI9673 (Part B), now in @JCO_ASCO: Addition of ipi to nivo did not improve survival for pts w/ met anal cancer. With that said, 👏 @theNCI ETCTN for acccruing largest comparative IO RCT to date for met anal cancer 👏 pts for participating -> trials for rare cancers ARE feasible to complete 👏 @theNCI for trial support -> unmet need to do better for anal cancer pts remains 👏 @CathyEngMD for leadership, and 👏 @MDAndersonNews team for 💪 accrual and commitment to translational science We keep moving on to do better and #endcancer for anal cancer… please come join the collaborative team! ascopubs.org/doi/10.1200/JC…

Gastric cancer is the fifth most diagnosed #cancer and the fifth leading cause of cancer-related deaths worldwide. This @JAMA_current Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #GastricCancer. ja.ma/45sjZyU

⏰ Dear #students, #residents and mentors! @ASCO medical student resident research forum is a wonderful opportunity to practice presentation skills and share your research in a low pressure environment. 🙏Case reports, series and retrospective efforts are all allowed! Don’t miss this great opportunity 💫 📸P.S. You’ll also get to meet legends of our field @jvonroennmd 👉 Apply by 1/12 tinyurl.com/5mb36fje #ASCO26 @ASCOTECAG @ASCOPres @OncoAlert @IMG_Oncologists @OncMedEdCoP @HemOncFellows @HemOncWomenDocs #MedEd #MedTwitter #OncTwitter

Abstracts #GI26 released! With dedicated KRAS session, 👇select KRAS abstracts #PancreaticCancer - more to come this yr! ➡️ combos I feel 🔑 Looking forward full presentations @ASCO @myESMO @OncoAlert

Elicio Therapeutics’ Phase 2 trial of its KRAS-targeted cancer vaccine shows promising results: 99% of evaluable pancreatic cancer patients mounted an immune response and 88% responded to their own tumor-specific mutation. investing.com/news/company-n…

Featured in @CancerTodayMag, Dr. Sara Char discusses @DanaFarber research that looks at the impact of pro- and anti-inflammatory diets on colon cancer outcomes. ➡️ bit.ly/48QeRFS

Brandon Huffman, MD, and @DanaFarber patient Debby spoke with @NBC10Boston's @MonicaNBCBoston about a potentially game-changing clinical trial offering a pill to treat #PancreaticCancer. November is #PancreaticCancerAwareness month. @DanaFarber_Hale ➡️ bit.ly/4ogwnIV

Exciting top-line data from HERIZON GEA-01. Will chemo+zani+tisle become the new SOC for 1L HER2pos #GEAs? Full data with toxicity awaited 👀⁦@BeOneMedicines⁩ ⁦@JazzPharma⁩ ⁦@WCMGIcancer⁩ ⁦@OncBrothers⁩ ⁦ ir.zymeworks.com/news-releases/…

This #PancreaticCancerAwarenessMonth, learn about hereditary risk and genetic testing with host @AlisynCamerota and Dr. Asaf Maoz from @DanaFarber. #PancChat (a Let's Win & @PanCAN collab) is found where you listen to podcasts!🎧 share.transistor.fm/s/298b4a81